drugset / Trial / NCT00468806

Study of Safety, Blood Levels and Brain Receptor Occupancy of GSK598809 Using PET Imaging in Health Males.

NCT00468806

Phase 1 Completed 25 enrolled GlaxoSmithKline
Non-randomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to look at how much of a new drug, GSK598809 binds to specific proteins in the brain and how much stays in the blood over a range of different doses.

Timeline

Start
2007-04
Primary completion
2008-05
Completion
2008-05

Drugs

EvaluationDrugModalityDoseRoute
Subject GSK598809 Unknown Oral

Indications

No indication recorded.